Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Maria Mavris"'
Publikováno v:
Frontiers in Medicine, Vol 8 (2022)
The European Medicines Agency provides Scientific Advice to medicines developers and patient input has been an integral part of this process for many years. As end users of medicines, patients bring their perspectives to many different processes alon
Externí odkaz:
https://doaj.org/article/e3b2123714904786873d7a1f64674cdb
Autor:
Muriel Vayssier-Taussat, Danielle Le Rhun, Hong Kuan Deng, Francis Biville, Sandra Cescau, Antoine Danchin, Geneviève Marignac, Evelyne Lenaour, Henri Jean Boulouis, Maria Mavris, Lionel Arnaud, Huanming Yang, Jing Wang, Maxime Quebatte, Philipp Engel, Henri Saenz, Christoph Dehio
Publikováno v:
PLoS Pathogens, Vol 6, Iss 6, p e1000946 (2010)
Bacterial pathogens typically infect only a limited range of hosts; however, the genetic mechanisms governing host-specificity are poorly understood. The alpha-proteobacterial genus Bartonella comprises 21 species that cause host-specific intraerythr
Externí odkaz:
https://doaj.org/article/06e645ff011546a4992a24115a4f7c41
Autor:
Maria Mavris, Lénaïg Halos
Publikováno v:
Emerging Infectious Diseases, Vol 11, Iss 4, Pp - (2005)
Externí odkaz:
https://doaj.org/article/d57264f7faf64479b4b7877449bbf5ef
Autor:
Stiina Aarum, Franz Koenig, Hanna Hedman, Matthias P. Hofer, Thorsten Vetter, Spiros Vamvakas, Martin Posch, Maria Mavris, Jan Regnstrom
Publikováno v:
Drug Discovery Today. 23:424-433
An analysis was performed on a data set of 157 orphan designated medicines with an outcome for marketing authorisation application (MAA) between 2000 and 2013. The intention was to understand the factors associated with marketing authorisation succes
Autor:
Gert van Valkenhoef, Beatriz Flores, Hans L. Hillege, Douwe Postmus, Francesco Pignatti, Eric Low, Maria Mavris, Isabelle Moulon, Tomas Salmonsson, Nathalie Bere, Jayne Galinsky, Sarah Richard
Publikováno v:
The Oncologist, 23(1), 44-51. ALPHAMED PRESS
The Oncologist
The Oncologist
The objectives of this study were to ascertain the treatment preferences of patients with multiple myeloma, considering benefits and risks of particular cancer treatments, and to illustrate how such data may be used to estimate patients' acceptance o
Autor:
Hans L. Hillege, Tomas Salmonson, Francesco Pignatti, Isabelle Moulon, Bettina Ryll, Douwe Postmus, Maria Mavris, Ananda Plate, Hans-Georg Eichler, Nathalie Bere
Publikováno v:
Clinical Pharmacology & Therapeutics, 99(5), 548-554. Nature Publishing Group
Currently, patient preference studies are not required to be included in marketing authorization applications to regulatory authorities, and the role and methodology for such studies have not been agreed upon. The European Medicines Agency (EMA) cond
Autor:
Mary Dunkle, Maria Mavris
Publikováno v:
Expert Opinion on Orphan Drugs. 2:1117-1121
Autor:
Frida Rivière, Jordi Llinares-Garcia, Guillaume Vaquer, Kerstin Westermark, Bruno Sepodes, Fabrizia Bignami, Maria Mavris
Publikováno v:
Nature Reviews Drug Discovery. 12:287-305
Animal models are important tools in the discovery and development of treatments for rare diseases, particularly given the small populations of patients in which to evaluate therapeutic candidates. Here, we provide a compilation of mammalian animal m
Autor:
Y. Le Cam, Maria Mavris
Publikováno v:
Molecular Syndromology. 3:237-243
Patients’ representatives have an increasingly present voice in all aspects of drug development from fundamental research through regulatory processes to health technology assessment. Although major advances have been made in raising awareness and
Autor:
Philippe J. Sansonetti, Kais Jamoussi, Maria Mavris, Hélène D'Hauteville, Christophe Penno, Elisabeth Ageron, Claude Parsot, Brigitte Demers
Publikováno v:
Molecular Microbiology. 56:1627-1635
Bacteria of Shigella spp. are responsible for shigellosis in humans and use a type III secretion (TTS) system to enter epithelial cells and trigger apoptosis in macrophages. Transit of translocator and effector proteins through the TTS apparatus is a